(redirected from Darunavir)
Also found in: Dictionary, Medical, Wikipedia.
Related to Darunavir: Raltegravir
Category filter:
DRVDirection de la Recherche et de la Valorisation (French: Department of Research and Valorisation)
DRVDemocratic Republic of Vietnam
DRVDarunavir (pharmaceutical drug-HIV treatment)
DRVDevice Driver (file name extension)
DRVDouay-Rheims Version (religious text)
DRVData Retention Voltage
DRVDouble Regulating Valve
DRVDietary Reference Value (nutrition)
DRVDevice Driver
DRVDriver File
DRVDaily Reference Value
DRVDiyala River Valley (Iraq)
DRVDirection des Ressources Vivantes (French: Direction of Living Resources, fisheries)
DRVDébit de Réfrigérant Variable (French: Variable Refrigerant Flow)
DRVDépartement Ressources Vivantes (French: Living Resources Department; research)
DRVDeutscher Raiffeisen Verband
DRVData Recovery Vehicle
DRVInstrument Driver Application Programming Interface
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Drugs that inhibit CYP3A4 [1, 6, 7, 11, 12], among them darunavir and other protease inhibitors, can raise the ergotamine concentration to toxic levels, even when ergotamine is administered at low doses [2, 6] (in this case patient was not taking any other medication which could interact with CYP3A4).
ART rejimi n=95 (%) TDF/FTC + LPV/r 45 (%47,4) TDF/FTC + DTG 16 (%16,8) TDF/FTC + EVG/c 15 (%15,8) TDF/FTC + RAL 13 (%13,7) TDF/FTC + EFV 5 (%5,3) TDF/FTC + DRV/ r 1 (%1,1) c: Kobisistat, DRV: Darunavir, DTG: Dolutegravir, EFV: Efavirenz, EVG: Elvitegravir, FTC: Emtrisitabin, LPV: Lopinavir, RAL: Raltegravir, r: Ritonavir, TDF: Tenofovir disoproksil fumarat Tablo 3.
The preferred regimens for starting treatment in the major international treatment guidelines have gradually moved towards an NRTI backbone of tenofovir disoproxil fumarate/ emtricitabine (TDF/FTC), tenofovir alafenamide/FTC (TAF/FTC) or abacavir/lamivudine (ABC/3TC) plus either the protease inhibitor (PI) darunavir (DRV) boosted by either ritonavir (r) or cobicistat (c), or the integrase inhibitors raltegravir (RAL), elvitegravir (ELV) or dolutegravir (DTG) or the non-nucleoside reverse transcriptase inhibitors rilpivirine (RPV) or efavirenz (EFV)--see EACS Guidelines.
(25) Even when boosted with ritonavir, the currently favored PIs darunavir (39,40) and atazanavir (40,41) upset lipids less than previous PIs.
Given the patient's clinical instability and unresponsiveness to supportive treatment, ART was empirically initiated with tenofovir/emtricitabine, darunavir, and ritonavir.
She had been taking antiretroviral drugs including tenofovir, emtricitabine, and boosted darunavir thereafter and achieved virological control after 6 months of therapy.
Incidence of dyslipidemia was found to be higher with LPV/r use than with darunavir and atazanavir use [9].
Darunavir (DRV) is a once-daily second-generation protease-inhibitor [1, 2] that is administered with low-dose ritonavir (DRV/r) and two nucleoside reverse transcriptase inhibitors (NRTI) for treatment of HIV infection.
PI-based regimen Darunavir (Prezista) and ritonavir (Norvir) plus tenofovir disoproxil fumarate/emtricitabine (Truvada).
All subjects were on antiretroviral regimens based upon either darunavir (Prezista), atazanavir (Reyataz), raltegravir (Isentress), or dolutegravir (Tivicay).